Alteogen signs $365 million SC platform deal as KEYTRUDA QLEX revenue jumps 262%
The South Korean biotech's third licensing agreement this year lifts 2026 deal value to $1.229 billion, while Merck's SC KEYTRUDA outpaced analyst estimates in the second quarter.